IL24 and non-small cell lung carcinoma: Given the promising preclinical data showcasing IL‐24's potential as an angiogenesis inhibitor, researchers have explored the therapeutic potential of IL‐24 in combination with bevacizumab, a recognized angiogenesis inhibitor, in NSCLC models.